SCHEMBL335165

SCHEMBL335165

CC(NCCN)c1cnn(C)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 2/20 0.40
OPRD1 P41143 1/20 0.40
NAMPT P43490 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HTT P42858 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
MET P08581 1/20 0.34
PDE1A P54750 1/20 0.34
PDE1B Q01064 1/20 0.34
PDE1C Q14123 1/20 0.34
RAB9A P51151 2/20 0.33
NPC1 O15118 1/20 0.33
IRAK4 Q9NWZ3 1/20 0.33
IDH1 O75874 1/20 0.33
GPR55 Q9Y2T6 1/20 0.32
GRN P28799 1/20 0.32
SORT1 Q99523 1/20 0.32
CYP3A4 P08684 2/20 0.32
MPO P05164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10244577 0.75 RAB9A (0.38) OPRM1OPRD1NAMPTALDH1A1HTT
SCHEMBL8251090 0.74 NAMPT (0.39) OPRM1OPRD1NAMPTALDH1A1HTT
SCHEMBL3727796 0.73 TAAR1 (0.42) OPRM1OPRD1ALDH1A1HTTSMN1; SMN2
SCHEMBL18575578 0.72 HTR1A (0.50) OPRM1OPRD1ALDH1A1HTTSMN1; SMN2
SCHEMBL335282 0.71 CYP3A4 (0.36) OPRM1ALDH1A1HTTSMN1; SMN2GPR55
SCHEMBL28802900 0.70
SCHEMBL2303823 0.70
SCHEMBL10862462 0.70 KAT2B (0.32) CPB2CPB1
SCHEMBL38661334 0.70 NAMPT (0.47) NAMPTALDH1A1HTTSMN1; SMN2L3MBTL1
SCHEMBL179280 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
EP-1985620-A1 10a-AZALIDE COMPOUND TAISHO PHARMACEUTICAL CO., LTD (JP) 2008-10-29 EP disclosed
EP-0192060-A1 Heterocyclic compounds NIHON BAYER AGROCHEM K.K. (JP) 1986-08-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 OPRM1 4835/4885OPRD1 4101/4885NAMPT 3116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.